To block TLR/IL1R-NF-κB inflammatory signaling pathways in CML LSCs in the presence of imatinib, we assessed the efficacy of IRAK1/4 inhibitor. This evidence concerns the gene IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive.